Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Non Operating Income (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Non Operating Income for 9 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • For Q4 2025, Non Operating Income changed N/A year-over-year to $3.8 million; the TTM value through Dec 2025 reached $11.5 million, changed N/A, while the annual FY2025 figure was $11.5 million, 2.92% down from the prior year.
  • Non Operating Income hit $3.8 million in Q4 2025 for Soleno Therapeutics, down from $3.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.9 million in Q3 2025 and bottomed at $1.8 million in Q2 2025.